Monday, 09 Dec 2019

You are here

Weight Loss Improves Psoriasis

Jennsen et al previously reported their findings regarding weight reductions ability to improve cutaneous psoriasis at the European Academy of Dermatology and Venereology (EADV) meeting in 2015, Now their results are published in The American Journal of Clinical Nutrition. (Citation source:,

They examined long-term outcomes of weight loss in 56 obese patients with a mean PASI score of 5.4 and a body mass index of 34.4 kg/m2. Patients were randomized to a low-energy diet (LED) group or a control group given general advice to eat healthy foods.

The diet consisted of 8 weeks of a low-energy liquid (fortified drinks and soups) diet (800-1,000 kcal) followed by 8 weeks in which regular foods were reintroduced at 1,200 kcal/day. Patients underwent a 64-week weight-loss program consisting of an initial 16-week randomized phase with an LED for 8 weeks and 8 weeks of normal food intake combined with 2 LED products/day, followed by a 48-week period of weight maintenance with the latter diet. After the randomization phase, the control group received the same 8 + 8-week LED intervention, and all patients were then followed for 48 weeks while on the weight-loss maintenance diet.

After the initial 16-wk LED-only period, the mean weight loss was −15.0 kg along with a decrease in PASI (-2.3) and DLQI (−2.3). At week 64, the mean weight loss compared with baseline was −10.1 kg and the PASI and DLQI reductions were maintained at −2.9 and −1.9, respectively.

Long-term weight loss in patients with psoriasis has long-lasting positive effects on the severity of psoriasis.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Secukinumab Improves Enthesitis

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week. 

Spondyloarthritis Affects Pregnancy Outcomes

A Danish registy has shown that the the prevalence of Spondyloarthritis (SpA) diagnosed prior to delivery has increased 5 fold in the last two decades and that SpA is associated with an increased risk of adverse pregnancy outcomes (APO).

IL-17 Inhibitors In Non-Radiographic Axial SpA

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Psoriatic Arthritis at ACR 2019

Below are several of the highlight studies in psoriatic arthritis (PsA) presented at the ACR 2019 annual meeting in Atlanta. 

New Treatments in Axial SpA from #ACR2019

There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS. The third area is the use of dual anti-IL17A and 17F drug bimekizumab in radiographic.